Futura Medical Regulatory News (FUM)

Futura Medical plc

("Futura" or "the Company")

AGM Statement

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, will hold its Annual General Meeting in London this morning.

At the meeting, John Clarke, Futura's Chairman, will make the following statement:

"This is my first AGM since joining Futura in February this year and I'm pleased to say that the current financial year has started well. We are moving closer to the launch of CSD500, our highly innovative condom, and will update shareholders on progress towards the launch as soon as we are able to do so. Elsewhere in our portfolio we look forward to the launch and roll-out beginning this summer in the US of PET500, our topical spray for enhanced sexual control.

"We also continue to make good progress in our earlier stage pipeline of products and in assessing new opportunities. A clinical study of our cellulite treatment, CRF100, is now fully recruited and is under way. We expect to announce the results of this study at about the time of our half year financial results in September."

For any further information please contact:

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com